Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2141.2009.07930.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
YTHDF1-targeting nanoassembly reverses tumoral immune evasion through epigenetics and cell cycle modulation.
J Control Release
February 2025
NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China. Electronic address:
YTHDF1, as a key mA reader protein, is believed to be one of the key mechanisms leading to tumor cell immune evasion and resistance via promoting MHC-I degradation. We explore therapeutic strategies that combine iron metabolism regulation with epigenetic regulation. Here, a nanoassembly that integrates Deferasirox (DFX, an FDA-approved iron chelator) and YTHDF1 siRNA (known as PPD/siYTHDF1) has been developed, which jointly promotes cell cycle arrest in tumor cells by interfering with iron metabolism and knocking down YTHDF1 protein.
View Article and Find Full Text PDFDeferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma.
Int J Mol Sci
February 2025
Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou 450001, China.
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with a poor prognosis and limited effective treatment options. This study investigates the therapeutic potential of Deferasirox (DFO), an iron chelator, in ESCC by targeting TAOK1, an STE20-type kinase implicated in cancer development. We demonstrate that DFO significantly inhibits the proliferation and colony formation of ESCC cells in a dose- and time-dependent manner.
View Article and Find Full Text PDFCase report: A novel 11-bp deletion in exon 11 causing a frameshift in the C-terminal of the gene leading to X-linked sideroblastic anemia-a family study.
Front Med (Lausanne)
February 2025
Department of Haematology, Sultan Qaboos University Hospital, Muscat, Oman.
X-linked sideroblastic anemia (XLSA) (MIM 300752) is the most common genetic form of sideroblastic anemia, a heterogeneous group of disorders characterized by iron deposits in the mitochondria of erythroid precursors. It is due to mutations of the erythroid-specific enzyme , the first enzyme of the heme biosynthetic pathway. Herein, we report a novel 11-bp deletion in exon 11 leading to a frameshift in the C-terminal region of the gene with a non-functional longer polypeptide of 614 amino acids leading to a loss-of-function mutation manifested as an X-linked sideroblastic anemia phenotype.
View Article and Find Full Text PDFDrug-induced liver injury from Deferasirox in a pediatric patient with hereditary spherocytosis: A case report.
JPGN Rep
February 2025
Division of Pediatric Gastroenterology, Department of Pediatrics UCSF Benioff Children's Hospital-Oakland Oakland California USA.
Patients with hereditary spherocytosis (HS) often require red blood cell transfusions for the treatment of hemolytic anemia. Iron overload is a known complication of frequent transfusions. Deferasirox, an oral iron chelator, can cause transient elevations in serum aminotransferase levels.
View Article and Find Full Text PDFenhances iron uptake to maintain fluconazole resistance.
Infect Immun
March 2025
Oral Microbiome Research Laboratory, Kornberg School of Dentistry, Temple University, Philadelphia, Pennsylvania, USA.
Widespread use of fluconazole has led to the emergence of fluconazole-resistant (FR) a spp. causing challenges in clinical treatment. Iron, an essential nutrient, affects the levels of ergosterol (a fluconazole target) in fungal membranes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!